8-KEarnings & ResultsExhibits & Filings

ELI LILLY & Co 8-K Report, Financial Results (Apr 16, 2007)

Filed April 16, 2007For Securities:LLY

Summary

Eli Lilly & Company (LLY) filed an 8-K on April 16, 2007, to report its first-quarter 2007 financial results and provide forward-looking guidance. The filing primarily consists of a press release and pro forma financial analysis, detailing operating performance and offering insights into expected future financial outcomes. Notably, the company utilizes non-GAAP financial measures, such as adjusted net income and earnings per share, to provide a clearer view of ongoing operations by excluding certain charges that can fluctuate significantly. Key adjustments for the first quarter of 2007 include restructuring charges related to manufacturing decisions and in-process research and development (R&D) charges stemming from the recent acquisition of ICOS Corporation and an in-licensing transaction with OSI Pharmaceuticals. To facilitate more meaningful year-over-year comparisons, Lilly also provided pro forma financial information, including an analysis assuming the ICOS acquisition had closed on January 1, 2006. This approach aims to help investors better understand underlying business trends and performance.

Key Highlights

  • 1Eli Lilly announced its Q1 2007 financial results via an 8-K filing on April 16, 2007.
  • 2The company is providing results and guidance using both GAAP and non-GAAP financial measures.
  • 3Non-GAAP measures like adjusted net income and EPS exclude specific charges to reflect ongoing operations.
  • 4Adjustments for Q1 2007 include restructuring charges and in-process R&D from ICOS acquisition and OSI in-licensing.
  • 5Pro forma financial analysis is provided to allow for better comparison with 2006, particularly regarding the ICOS acquisition.
  • 6Guidance for Q2 and full-year 2007 is provided on both GAAP and adjusted/pro forma bases.
  • 7The ICOS acquisition closed on January 29, 2007, impacting current period results.

Frequently Asked Questions

The main purpose of this 8-K filing is to announce Eli Lilly's financial results for the first quarter ended March 31, 2007, and to provide financial guidance for the second quarter and full year 2007. It also includes attachments like a press release and pro forma financial analysis.

Eli Lilly uses non-GAAP financial measures, such as adjusted net income and adjusted earnings per share, to provide investors with a clearer view of the company's ongoing operational performance. These measures exclude items like restructuring charges and in-process R&D costs, which can be highly variable and difficult to predict, thereby helping investors make more meaningful period-over-period comparisons and identify underlying business trends.

Significant events impacting the reported results include the acquisition of ICOS Corporation, which closed on January 29, 2007, and an in-licensing transaction with OSI Pharmaceuticals. These events led to in-process research and development charges. Additionally, restructuring charges associated with manufacturing decisions are also impacting the reported figures.

The pro forma financial analysis is provided to help investors make more meaningful comparisons between 2007 and 2006 results. Specifically, it adjusts for the impact of the ICOS acquisition, presenting results as if the acquisition had occurred on January 1, 2006. This helps to isolate the impact of the acquisition on period-over-period performance.